diffusion through a membrane over time.

2. Scope

This SOP applies to Analytical Method Development personnel involved in the evaluation of drug release profiles from topical gels using Franz-type or equivalent vertical diffusion cells during formulation development and batch-to-batch consistency testing.

3. Responsibilities

• Analytical Scientist: Responsible for operating the diffusion cells, sampling, analysis, and data processing.
• QC Analyst: Assists in membrane preparation, receptor medium preparation, and equipment setup.
• QA Executive: Ensures the method is validated, results are reviewed, and SOP compliance is maintained.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that drug diffusion testing is conducted in compliance with industry standards and regulatory requirements.

5. Procedure

5.1 Apparatus and Materials

1. Franz Diffusion Cells or equivalent (with receptor volume: 5–7 mL)
2. Synthetic membranes (e.g., cellulose nitrate, 0.45 µm)
3. Water bath with magnetic stirring and temperature control (32 ± 0.5°C)
4. HPLC or UV-visible spectrophotometer
5. Receptor medium: Phosphate buffer, methanol:water, or any validated solvent

5.2 Membrane Preparation

1. Soak the membrane in receptor medium for 30 minutes at room temperature.
2. Inspect for defects; use only intact membranes.

5.3 Sample Application

1. Accurately weigh 500 mg of gel formulation and spread uniformly onto the membrane surface in the donor chamber.
2. Clamp donor and receptor compartments ensuring no leakage.

5.4 Testing Conditions

1. Maintain receptor fluid at 32 ± 0.5°C with constant stirring.
2. Withdraw 0.5 mL samples at predetermined intervals (e.g., 0.5, 1, 2, 3, 4, 6 hours).
3. Immediately replace withdrawn volume with fresh receptor medium maintained at same temperature.
4. Filter samples through 0.45 µm filters prior to analysis.

5.5 Analytical Method

1. HPLC Conditions (Example):
   • Column: C18, 150 mm × 4.6 mm, 5 µm
   • Mobile Phase: Methanol:Water (70:30) with 0.1% formic acid
   • Flow Rate: 1.0 mL/min
   • Detection: UV at 240 nm
2. UV Conditions (alternative): λmax specific to API, e.g., 265 nm

5.6 Calculation

Drug Release (µg/cm²) = (Concentration × Receptor Volume) / Membrane Area

5.7 Data Interpretation

1. Plot drug release (µg/cm²) vs. square root of time (√t).
2. Calculate slope, R² value, and compare release profiles between batches.

5.8 Method Validation Parameters

1. Linearity, Accuracy, Precision (% RSD ≤ 5%), and Specificity
2. Robustness: Assessed by changes in membrane type or receptor volume

5.9 Acceptance Criteria

• RSD across cells: ≤ 15%
• Linear drug release profile (R² ≥ 0.95)

6. Abbreviations

• IVRT: In-vitro Release Testing
• RSD: Relative Standard Deviation
• QA: Quality Assurance
• HPLC: High Performance Liquid Chromatography

7. Documents

1. Drug Diffusion Data Log – Annexure-1
2. Membrane Quality Check Log – Annexure-2
3. Validation Report – Annexure-3

8. References

• FDA SUPAC-SS Guidance: Nonsterile Semisolid Dosage Forms
• USP <1724>: Semisolid Drug Products – Performance Tests
• ICH Q2(R1): Validation of Analytical Procedures

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name	Neha Kulkarni	Prateek Sharma	Sunita Reddy
Designation	Analytical Scientist	QA Reviewer	Head – AMD
Department	Analytical Method Development	QA	Analytical Method Development

11. Annexures

Annexure-1: Drug Diffusion Data Log

Time (hrs)	Concentration (µg/mL)	Drug Release (µg/cm²)
1	7.8	23.5
2	14.2	42.8
4	26.3	79.2

Annexure-2: Membrane Quality Check Log

Membrane Type	Lot No.	Pre-use Integrity Check	Status	Verified By
Cellulose Nitrate	CN2025-07	No defects	Pass	Prateek Sharma

Annexure-3: Validation Report Summary

The method was validated for linearity (r = 0.9992), precision (% RSD = 1.9%), and accuracy (recoveries 98.6%–101.4%). Diffusion data showed consistent release rates across multiple batches, confirming suitability for routine IVRT evaluation.

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
21/05/2025	2.0	Expanded validation parameters and clarified data analysis	Annual Review	Sunita Reddy
10/04/2022	1.0	Initial SOP Release	New SOP	QA Head